Organ-Confined Prostate Cancer: Are We Moving Towards More or Less Radical Surgical Intervention?

Current Urology Reports

Volumn 16, Issue 5, 2015, Pages

  Stevens, Daniel J ^a,b   Sharma, Naomi L ^b   Tewari, Ashutosh K ^d   Kirby, Roger ^e   Sooriakumaran, Prasanna ^b,c,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Prostate Centre   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Brachytherapy; Prostate cancer; Radical prostatectomy; Radiotherapy; Urosurgery

Indexed keywords

CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; ERECTILE DYSFUNCTION; FOLLOW UP; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; INTESTINE FUNCTION; LIBIDO; LIFE EXPECTANCY; MEDICARE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PROPENSITY SCORE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROBOTICS; SEXUAL FUNCTION; URINE INCONTINENCE; UROLOGIST; CANCER STAGING; DECISION MAKING; MALE; PROSTATIC NEOPLASMS;

DECISION MAKING; HUMANS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84925115666     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-015-0504-z     Document Type: Review

References (38)

1. Athene Lane J, Donovan JL, David M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol. 2014;15(10):1109–18. Important baseline details and recruitment information for the soon to be published ProtecT RCT.
2. Makarov DV, Trock BJ, Humphreys ED, et al. Updated nomogram to predict pathologic state of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095–101.
3. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2014;370:932–42. Updated results from the SPCG-4 trial.
4. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localised prostate cancer. N Engl J Med. 2012;367:203–13. Results of the PIVOT trial.
5. Roobol MJ, Bokhorst LP. The ProtecT trial: what can we expect? Lancet Oncol. 2014;15(10):1046–7.
6. Kates M, Tosoian J, Trock BJ et al. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJUI. 2014; 12828
7. Surcel CI, Sooriakumaran P, Briganti A et al. Preferences for the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. BJUI Int. 2014; 12796
8. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74. Seminal paper comparing outcomes following treatment for prostate cancer.
9. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28(9):1508–13.
10. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20(16):3376–85.
11. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJUI. 2012;109(1):22–9.
12. Cooperberg MR, Vickers AJ, Broering JM, et al. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226–34.
13. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–17.
14. Sun M, Sammon JD, Becker A, et al. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJUI. 2014;113:200–8. High quality recently published observational study.
15. Hoffman RM, Koyama T, Kang-Hsien F, et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. JNCI. 2013;105(10):711–8. High quality recently published observational study.
16. Daskivich TJ, Chamie K, Kwan L, et al. Improved prediction of long-term, other cause mortality in men with prostate cancer. J Urol. 2011;186(5):1868–73.
17. Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:1502. Recently published observational study with near complete high quality dataset.
18. Stattin P, Loeb S, et al. “To measure is to know. If you cannot measure it, you cannot improve it”: statistical modeling cannot compensate for unmeasured bias. Eur Urol. 2014;65(4):701–3.
19. Rane A. Surgery or radiotherapy for prostate cancer? BMJ. 2014;348:g1580.
20. Matthew AG, Alibhai SM, Davidson T, et al. Health-related quality of life following radical prostatectomy: long term outcomes. Qual Life Res. 2014;23(8):2309–17.
21. Shroeck FL, Krupski T, Sun L, et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008;54(4):785–93.
22. Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 2014;15(2):223–31.
23. Schuessler WW, Schulmam PG, Clayman RV, et al. Laparoscopic radical prostatectomy: initial short-term experience. Urology. 1997;50(6):854–7.
24. Mayer EK, Winkler MH, Aggarwal R, et al. Robotic prostatectomy: the first UK experience. Int J Med Robot. 2006;2(4):321–8.
25. Novara G, Ficarra V, Mocellin S, et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):382–404.
26. Novara G, Ficarra V, Rosen R, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):431–52.
27. [http://www.baus.org.uk/Resources/BAUS/Documents/PDF%20Documents/Data%20and%20Audit/RadProsSnapshotPoster2012.pdf] Accessed 06/12/14.
28. Sooriakumaran P, Haendler L, Nyberg T, et al. Biochemical recurrence after robot-assisted radical prostatectomy in a european single-centre cohort with a minimum follow-up time of 5 years. Eur Urol. 2012;62(5):768–74.
29. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185–90.
30. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012;156(8):591–5.
31. Shoots I, Petrides N, Giganti F, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2014;10(050):S0302–2838.
32. Sooriakumaran P, Calway A, Sagalovich D, et al. The impact of multiple biopsies on outcomes of nerve-sparing robotic-assisted radical prostatectomy. Int J Impot Res. 2012;24(4):161–4.
33. Barret E, Ahallal Y, Sanchez-Salas R, et al. Morbidity of focal therapy in the treatment of localised prostate cancer. Eur Urol. 2013;63:618–22.
34. Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for localised prostate cancer: a phase I/II trial. J Urol. 2011;185:1246–54.
35. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13:622–32.
36. Bahn D, de Castro Abeu AL, Gill IS, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012;62:55–63.
37. Haffner M, Mosbruger T, Esopi DM, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918–22.
38. Dickinson L, Ahmed HU, Kirkham AP, et al. A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study. Contemp Clin Trials. 2013;36(1):68–80.